9 news items
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
12 Jun 24
:Denise Chua, MBA, CLS, MT (ASCP)Vice President, Investor Relations and Corporate Communications949-396-6830
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
3 Jun 24
)Vice President, Investor Relations and Corporate Communications949-396-6830
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
:Denise Chua, MBA, CLS, MT (ASCP)Vice President, Investor Relations and Corporate Communications949-396-6830
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
Relations and Corporate Communications949-396-6830
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
NKGN
16 May 24
President, Investor Relations and Corporate Communications949-396-6830
ckhg3twarka9ixaqzqgnvp6rau pwdd5xgep6z0bbekywkakr15h1sjvnjw
NKGN
25 Apr 24
:Denise Chua, MBA, CLS, MT (ASCP)Vice President, Investor Relations and Corporate Communications949-396-6830
2l6jhlg3rd9zmhzsj3w15442i6e5oqh5095w51233m0y727s3pm09l1
NKGN
24 Apr 24
:
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
949-396-6830
ig4irhh2cu44l8wtfa7irniqlcisnx9oa5j47ws3y60yi
NKGN
11 Apr 24
)Vice President, Investor Relations and Corporate Communications949-396-6830
gdegcnwuxlou5i3jc0j2yit4570043vimz45lu0tq2yjjgdjm
NKGN
25 Mar 24
Communications949-396-6830
- Prev
- 1
- Next